Biotechnology for a Conservative Japanese Drug Industry
Japanese drug companies remain high conservative, reluctant to expand beyond a national or regional focus to create worldwide pharmaceutical businesses. More are turning to biotech collaborations to provide new products, particularly favoring combinatorial chemistry deals which are relatively inexpensive and have short-term payoffs.
You may also be interested in...
While endocrine-disrupting evidence was inconclusive, the Scientific Committee on Consumer Safety recommends more conservative limits on use of homosalate, octocrylene and benzophenone-3 in cosmetic products compared with current requirements under the European Cosmetics Product Regulation.
The risk of inadvertently growing SARS-CoV-2 virus in cell and gene therapies and possibly infecting patients and workers should be assessed and mitigated, the agency advises.
Move was meant to preempt others’ efforts to secure the next six months of Regeneron’s COVID-19 antibody therapeutic.